4 ms·
Sometimes I wonder if we wouldn't be better with real centrally planned drug production, even with all the negatives that implies. Then I remember that any sys
by Symmetry 13y ago
Sometimes I wonder if we wouldn't be better with real centrally planned drug production, even with all the negatives that implies. Then I remember that any system will inevitably result in mistakes, Congresswill respond to those mistakes with overbroad rules that restrict the planner, and we'll end up in an even worse situation.
Well, I don't know. The recent FDA drug quality crackdown has probably saved a few lives at the cost of hundreds dieing from drug shortages. The problem is that the former number is much more squarely within the FDA's regulatory perview thant he later, giving them equal weight. Maybe if we had an organization equally responsible for both numbers we'd see better outcomes.
ut then again, any beaurocratic boundaries will be unnatural at times, and you have to divide up departments somehow. I'm not sure any alternative organization wouldn't result in equally perverse outcomes.
And on the gripping hand, regulators in Europe have somehow managed to avoid this problem entirely, so we should probably just copy what they're doing. But I suppose if that was realistic we would have copied the Swiss or Sinaporeans instead of passing the ACA.
- jjoonathan 13y ago> regulators in Europe have somehow managed to avoid this problem entirely > Maybe if we had an organization equally responsible for both numbers we'd see better outcomes. It's not a "somehow" -- you answered your own question! Add this to the long list of reasons why we should switch to single payer.
- Symmetry 13y agoExcept it's not actually the same bureaucratic entity that does both. The government may pay for health care but in many countries like France hospitals are still private businesses. I think the real difference more different levels of social trust in experts, parliamentary systems versus presidential systems, etc.
- _delirium 13y agoFrance has a hybrid system, where everyone is covered by the public system, but you can also choose to purchase care privately if you prefer. But most hospitals are publicly owned. The breakdown is about 60% public, 25% for-profit business, 15% nonprofit organization. Source for the numbers: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_rs_bds2&lang=en http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth...
- roc 13y ago> "Sometimes I wonder if we wouldn't be better with real centrally planned drug production" Or we could simply subsidize the modest overproduction of such critical, low-profit generics, selling or donating any surplus [1] not unlike what we do with food staples. This would encourage additional production, making any drops, for whatever reasons (regulatory, accidental, business-related) less of a systemic threat. In a world of imperfect solutions, I'll take that over additional regulatory bureaucracy or central planning. [1] I realize this isn't ideal and 'dumping' the surplus may well do more long-term harm in any communities we might help, short term, via donation. But that can be studied and determined. And, frankly, a robust public health system is important enough that even if we have to incinerate the surplus, subsidized overproduction may well be worth doing.
- refurb 13y agoWhat makes you think Europe has avoided the issue? They are having drug shortage problems of their own. http://www.policymed.com/2013/02/the-european-medicines-agency-mitigating-drug-shortages-in-europe.html http://www.policymed.com/2013/02/the-european-medicines-agen... This has nothing to do with the reimbursement system at all. Drug shortages are on the manufacturing side.
- rayiner 13y ago> The recent FDA drug quality crackdown has probably saved a few lives at the cost of hundreds dieing from drug shortages. We're playing with bigger numbers here. E.g. estimates were that Vioxx resulted in 90-140k additional cases of heart disease. The $5 billion paid in settlement of claims is a fraction of the actual damages, as settlements necessarily are.
- temphn 13y agoEven if you believe Nissen, the actual increase in risk was from .3 to .6%, and people who were denied Vioxx still want it back. An arthritis drug that vastly improves my life with probability 1 while maybe shortening it with some small probability is one that people should be free to choose, or not choose. You don't have the ethical right to dictate someone else's medical decisions.
- abtinf 13y agoThe problem is that drug production is centrally planned. Manufacturers must coordinate with the FDA for everything - when they are going to start production, how much they are going to produce, exactly how they will produce it, and so forth. This is a process that takes a significant amount of time. Thus, when there is a "shortage", a manufacturer can't simply increase the production run. Nor can others step in and also start producing in the near term. So people die. All shortages are, by definition, caused by the government.